retatrutide clinical trial results weight loss retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Lilly's triple agonist achieves 16.8%

Regehr WG, Tank DW (1991)

At Conway Medical Center, weve been safeguarding the health of the Conway and Myrtle Beach area for a century, constantly seeking innovative treatments to serve our community better

H., Guz, Y., Grigoryan, M

** Daily Value not established.

These enzymes contribute to the epigenetic regulation of gene expression by catalyzing reactions involved in the demethylation of DNA and histones

ZepBound, launched for obesity in late 2023, quickly added hundreds of millions in sales by mid-2025, its global sales were already in the hundreds of millions as clinics rolled out the new weight-loss injection